What is Foghorn Therapeutics Price-to-Free-Cash-Flow?
As of today (2024-04-29), Foghorn Therapeutics's share price is $5.49.
Foghorn Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.84. Hence, Foghorn Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Foghorn Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 6 years, Foghorn Therapeutics's highest Price-to-Free-Cash-Flow Ratio was 3.22. The lowest was 1.00. And the median was 1.79.
FHTX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.52 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Foghorn Therapeutics was -161.50% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 12.90% per year.
During the past 6 years, Foghorn Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 12.90% per year. The lowest was -5.40% per year. And the median was 3.75% per year.
Foghorn Therapeutics Price-to-Free-Cash-Flow Historical Data
The historical data trend for Foghorn Therapeutics's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Foghorn Therapeutics's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Foghorn Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foghorn Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's Price-to-Free-Cash-Flow falls into.
Foghorn Therapeutics's Share Price of today is $5.49. Foghorn Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.84.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Foghorn Therapeutics Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Foghorn Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Foghorn Therapeutics (Foghorn Therapeutics) Business Description
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FHTX has been successfully added to your 